Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference - Cancelled

Due to the impact of COVID-19, the MYSummit Conference
has been cancelled

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Featured Content

Myeloma News

Treating COVID-19 in a patient with multiple myeloma

Source: Multiple Myeloma News -- ScienceDaily A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report...

Recent Publications

Twitter Discussions

MM_Hub: CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma

CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma...

MM_Hub: CONGRESS|#EHA2021| @H_Einsele, University Hospital Wurzburg discussed novel strategies like dual targeting CAR-T cells, Tri-specific T cell engaging Abs, drugs& combination with checkpoint blockers are opening new options for T cell redirecting strategies #mmsm, #myeloma

CONGRESS|#EHA2021| @H_Einsele, University Hospital Wurzburg discussed novel strategies like dual targeting CAR-T cells, Tri-specific T cell engaging Abs, drugs& combination with checkpoint blockers are opening new options for T cell redirecting strategies #mmsm,...

MM_Hub: CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine

CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine pic.twitter.com/d846109i7Y— Multiple Myeloma Hub...

MM_Hub: CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm #myeloma

CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm...